FDA批准礼来胃癌新药Cyramza --- 礼来制药公司(Eli Lilly and Company)研发的Cyramza(ramucirumab)是一种血管生成抑制剂(靶向VEGF的全人源化IgG1单抗),其适应症为晚期胃癌或胃食管交界部腺癌。临床研究显示,Cyramza较安慰剂可更有效地改善总体生存期(5.2个月和3.8个月),此外 Cyramza与紫杉醇(paclitaxel)联用时亦可更有效地改善生存期。常见的副作用有腹泻和高血压。
The U.S. Food and Drug Administration today approved Cyramza (ramucirumab) to treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma, a form of cancer located in the region where the esophagus joins the stomach.
......
来源: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm394107.htm
--------------------------------------------------------------------------------------
附加:
乳癌患者在确诊后增加维生素C的摄入量可能有助降低死亡风险---来自EJC (《欧洲癌症杂志》) 的一篇meta分析文章显示,乳癌患者在确诊后开始服用维生素C补充剂、或增加膳食中的维生素C摄入量,可能具有降低死亡风险的作用。后者的作用更为显著。
详见 http://www.ejcancer.com/Vitamin C and survival among women with breast cancer: A Meta-analysis